The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Two new PD-(L)1 x VEGF projects have entered the clinic.
The private ADC company is being wound down.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
